172 related articles for article (PubMed ID: 12085221)
1. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
Blower P; Aapro M
Br J Cancer; 2002 May; 86(10):1662-3; author reply 1664. PubMed ID: 12085221
[No Abstract] [Full Text] [Related]
2. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
del Giglio A; Soares HP; Caparroz C; Castro PC
Cancer; 2000 Dec; 89(11):2301-8. PubMed ID: 11147601
[TBL] [Abstract][Full Text] [Related]
3. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
4. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
5. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
6. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
Lindley C; Blower P
Am J Health Syst Pharm; 2000 Sep; 57(18):1685-97. PubMed ID: 11006796
[TBL] [Abstract][Full Text] [Related]
7. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
Oge A; Alkiş N; Oge O; Kartum A
J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
[TBL] [Abstract][Full Text] [Related]
8. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Alon E; Biro P
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 May; 31(4):200-4. PubMed ID: 8704077
[TBL] [Abstract][Full Text] [Related]
9. '... setron': are 5-HT3 receptor antagonists different?
Aapro MS
Eur J Cancer; 1993; 29A(12):1655. PubMed ID: 8398287
[No Abstract] [Full Text] [Related]
10. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
[TBL] [Abstract][Full Text] [Related]
11. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
Jantunen IT; Muhonen TT; Kataja VV; Flander MK; Teerenhovi L
Eur J Cancer; 1993; 29A(12):1669-72. PubMed ID: 8398291
[TBL] [Abstract][Full Text] [Related]
12. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
Endo T; Sugawara J; Nemoto M; Minami M; Blower PR
Res Commun Mol Pathol Pharmacol; 1998 Dec; 102(3):227-39. PubMed ID: 10342910
[TBL] [Abstract][Full Text] [Related]
13. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
Vrabel M
Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
Jordan K; Hinke A; Grothey A; Voigt W; Arnold D; Wolf HH; Schmoll HJ
Support Care Cancer; 2007 Sep; 15(9):1023-33. PubMed ID: 17205281
[TBL] [Abstract][Full Text] [Related]
15. [Serotonin and anticancer drug-induced emesis].
Minami M; Endo T; Hamaue N; Hirafuji M
Yakugaku Zasshi; 2004 Aug; 124(8):491-507. PubMed ID: 15297719
[TBL] [Abstract][Full Text] [Related]
16. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
17. Are there differences among the serotonin antagonists?
Tonato M; Roila F; Del Favero A
Support Care Cancer; 1994 Sep; 2(5):293-6. PubMed ID: 8000725
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration.
Corrigan BW; Nicholls B; Thakrar B; Lam R; Grosse C; Alianti J; Palmer JL
Drug Metab Dispos; 1999 Jan; 27(1):110-2. PubMed ID: 9884318
[TBL] [Abstract][Full Text] [Related]
19. Use of dexamethasone with 5-HT3-receptor antagonists.
Perez EA
Oncology (Williston Park); 1996 Jan; 10(1):14. PubMed ID: 8924363
[No Abstract] [Full Text] [Related]
20. Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus.
Horikoshi K; Yokoyama T; Kishibayashi N; Ohmori K; Ishii A; Karasawa A
Jpn J Pharmacol; 2001 Jan; 85(1):70-4. PubMed ID: 11243577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]